2014, Number 10
<< Back Next >>
MediSan 2014; 18 (10)
Antimicrobial treatment in patients with lower breathing disorders Dra.
Riverón PI, Legrá AN, Del Campo ME, Grave PYT, Silvera DS
Language: Spanish
References: 15
Page:
PDF size: 54.70 Kb.
ABSTRACT
An observational, descriptive and cross sectional study of 556 patients with lower
breathing infections, admitted to the Pneumology Service of "Juan Bruno Zayas
Alfonso" Teaching General Hospital in Santiago de Cuba was carried out during the
2012, with the aim evaluating the use of antimicrobials on them. The Guide for
the antimicrobians was used (OPS 2007-2008), and the corresponding medical
records were reviewed. For the analysis of the data the statistical package SPSS
version 11 was used. Among the antimicrobians used there were: cephalosporins,
macrolides, aminoglycosides and penicillins; but the combination of cephalosporins
and macrolides was the most used. Men older than 60 years, pneumonia and lung
obstructive chronic disease, exacerbated by breathing infection (coming from the
community),prevailed in the series as the main clinical entities requiring antibiotics.
The prescribed treatment allowed the favorable clinical course of the patients.
REFERENCES
Cires Pujol M. La resistencia a los antimicrobianos, un problema mundial. Rev Cubana Med Gen Integr. 2002 [citado 8 Feb 2013];18(2).
Siegel JD, Rhinehart E, Jackson M, Chiarello L, the Healthcare Infection Control Practices Advisory Committee (HICPAC), management of multidrug-resistant organisms in healthcare settings, 2006. [citado 8 Feb 2013].
Vidaur L, Sirgo G, Rodríguez AH, Rello J. Clinical approach to the patient with suspected ventilator associated pneumonia. Respir Care. 2005;50(7):965-74.
Kasper DL, Braunwald E, Hauser S, Longo D, Jameson JL, Fauci AS. Harrison’s Principles of Internal Medicine. 16 ed. New York: McGraw Hill; 2005.
Grupo de Trabajo del Consenso EPOC de NEUMOSUR, SEMERGEN-Andalucia y SAMFyC. Documento de consenso sobre enfermedad pulmonar obstructiva crónica en Andalucía-2010. Rev Esp Patol Torac. 2010;22(4):275-309.
Vidaur L, Sirgo G, Rodríguez AH, Rello J. Clinical approach to the patient with suspected ventilator associated pneumonia. Respir Care. 2005;50(7):965-74.
Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001;163(7):1730-54.
Acosta Fernández O, Batista Martín JJ, Cabrera Navarro P, Caminero Luna JA, Carrillo Díaz T, Casanova Macario C, et al. Manual de enfermedades respiratorias. 2 ed. España: ICTER; 2005.
Grupo de Trabajo del Consenso EPOC de NEUMOSUR, SEMERGEN-Andalucia y SAMFyC. Documento de consenso sobre enfermedad pulmonar obstructiva crónica en Andalucía-2010. Rev Esp Patol Torac. 2010;22(4):275-309. MEDISAN 2014; 18(10):1378
Cires Pujol M. La resistencia a los antimicrobianos, un problema mundial. Rev Cubana Med Gen Integr. 2002 [citado 8 Feb 2013];18(2).
Kasper DL, Braunwald E, Hauser S, Longo D, Jameson JL, Fauci AS. Harrison’s Principles of Internal Medicine. 16 ed. New York: McGraw Hill; 2005.
WHO Collaborating Centre for Drug Statistics. Anatomical Therapeutic Chemical (ATC). Classification and Defined Daily Doses (DDD). Norway: Oslo; 1993.
Acosta Fernández O, Batista Martín JJ, Cabrera Navarro P, Caminero Luna JA, Carrillo Díaz T, Casanova Macario C, et al. Manual de enfermedades respiratorias. 2 ed. España: ICTER; 2005.
Peña Machado MA. Antibacterianos. En: Morón Rodríguez FJ, Borroto Regalado R, Calvo Barbado DM, Cires Pujol M, Cruz barrios MA, Fernández García A, et al. Farmacología Clínica. La Habana: Editorial Ciencias Médicas; 2008. p. 409-41.
Polk RE, Fox C, Mahoney A, Letcavage J, MacDougall C. Measurement of adult antibacterial drug use in 130 US hospitals: comparison of defined daily dose and days of therapy. Clin Infect Dis. 2007;44(5):664–70.